Company: STAA
Filing Date: 2025-10-09
Form Type: DFAN14A
Source: 0001213900-25-097833
Chunk: 9

Company: STAAR SURGICAL CO
Filing Date: 2025-10-09
Form: DFAN14A
Chunk 9
---
 glad to
be rid of this dog, shareholders”:

“We believe the transaction with
Alcon represents the best path forward and provides the greatest value for STAAR shareholders,” said Stephen Farrell, CEO of STAAR.
“As we’ve shared, fluctuating demand in China over the past two years has continued to create significant headwinds for STAAR
as a standalone company. I’m proud of our team’s efforts to address recent challenges, but there is more work to do. As a
significantly larger company, Alcon has the capabilities and scale to accelerate EVO ICL adoption and bring our innovative technology
to more surgeons and patients worldwide.”

Dr. Elizabeth Yeu, Chair of the STAAR
Board of Directors, said, “The STAAR Board is committed to maximizing value for shareholders. We have determined that this carefully
negotiated transaction is in the best interest of STAAR shareholders as it delivers immediate and certain value at a significant premium,
value that exceeds what we believe could be achieved under STAAR’s standalone strategy.”

| 4. | In certain broker-dealer models you could then buy from the                                                                              
 sellers at $25, sell to the buyers at $40, and clip the $15 spread, but that is not generally a possibility that is open to the managers 
 of a public company. You have to get agreement on one price, but it's easier to get agreement if the sellers are pessimistic and the     
 buyers are optimistic.                                                                                                                   |

<div align='center'>Exhibit 2-3</div>

Subsequent communications to shareholdrs have
been even gloomier; here’s one from Monday quoting pessimistic research analysts and noting that “prior to the Alcon
transaction, the median sell-side analyst price target for STAAR was only $19.00 per share.” (The shareholders will vote on the
deal on Oct. 23.) But the shareholders are not all pleased. Today Broadwood Partners LP, which owns 27.5% of STAAR’s stock, put
out a press release:

Management spent most of 2025 publicly
touting the progress on its turnaround plan, while assuring investors that short-term challenges were abating and that STAAR’s future
was bright.

That was before the management team
realized it could make tens of millions of dollars quickly by selling STAAR to Alcon, even for a woefully inadequate price of $28 per
share.

As recently as July 23, 2025, management